Mohamed Abdulla Ghuloom Abdulla Bucheeri, Kareem Khalaf, Huaqi Li, Yuhong Yuan, Daniel Tham, Reyana Jayawardena, Balqis Alabdulkarim, Jeffrey D Mosko, Christopher W Teshima, Gary R May, Natalia Causada Calo
{"title":"Prevalence and impact of sarcopenia in chronic pancreatitis: A systematic review and meta-analysis.","authors":"Mohamed Abdulla Ghuloom Abdulla Bucheeri, Kareem Khalaf, Huaqi Li, Yuhong Yuan, Daniel Tham, Reyana Jayawardena, Balqis Alabdulkarim, Jeffrey D Mosko, Christopher W Teshima, Gary R May, Natalia Causada Calo","doi":"10.1016/j.pan.2025.09.026","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic pancreatitis (CP) is a progressive inflammatory disease leading to irreversible pancreatic damage, resulting in exocrine and endocrine insufficiency. While surgical and endoscopic interventions can address morphological complications of CP, they may not directly address the systemic impacts of malnutrition, frailty, and sarcopenia-key contributors to morbidity and mortality in these patients. This systematic review and meta-analysis aimed to evaluate the prevalence of sarcopenia in CP patients.</p><p><strong>Methods: </strong>A systematic search of MEDLINE and Embase databases (via Ovid, from inception to November 2024) was conducted following PRISMA guidelines. Studies reporting sarcopenia prevalence in CP, assessed by various diagnostic modalities, were included. Random-effects pooled proportion meta-analysis using the Freeman-Tukey double arcsine transformation were applied. Heterogeneity was assessed using the I<sup>2</sup> statistic.</p><p><strong>Results: </strong>Fifteen studies with 1365 CP patients were included. Most patients were male (68 %), with about half having a history of alcohol misuse and smoking (48 %, 52.5 %, respectively). About 47 % had pancreatic exocrine insufficiency, with 41 % being on pancreatic enzyme replacement therapy. Mortality was assessed in a single study and reported at 16 %. The pooled prevalence of sarcopenia was 40.9 % [95 % CI: 28.4 %-58.9 %]. The pooled mean difference for BMI between sarcopenic and non-sarcopenic patients was -2.62 (95 % CI: 3.22 to -2.01, p < 0.01).</p><p><strong>Conclusion: </strong>This highlights that approximately 41 % of patients with CP have sarcopenia, and that this seems to be associated with a low BMI. Given the known adverse impact of sarcopenia on overall health, future studies should focus on standardizing sarcopenia screening, assessment and exploring its interplay with outcomes in CP patients.</p><p><strong>Prospero: </strong>CRD42024611097.</p>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.pan.2025.09.026","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chronic pancreatitis (CP) is a progressive inflammatory disease leading to irreversible pancreatic damage, resulting in exocrine and endocrine insufficiency. While surgical and endoscopic interventions can address morphological complications of CP, they may not directly address the systemic impacts of malnutrition, frailty, and sarcopenia-key contributors to morbidity and mortality in these patients. This systematic review and meta-analysis aimed to evaluate the prevalence of sarcopenia in CP patients.
Methods: A systematic search of MEDLINE and Embase databases (via Ovid, from inception to November 2024) was conducted following PRISMA guidelines. Studies reporting sarcopenia prevalence in CP, assessed by various diagnostic modalities, were included. Random-effects pooled proportion meta-analysis using the Freeman-Tukey double arcsine transformation were applied. Heterogeneity was assessed using the I2 statistic.
Results: Fifteen studies with 1365 CP patients were included. Most patients were male (68 %), with about half having a history of alcohol misuse and smoking (48 %, 52.5 %, respectively). About 47 % had pancreatic exocrine insufficiency, with 41 % being on pancreatic enzyme replacement therapy. Mortality was assessed in a single study and reported at 16 %. The pooled prevalence of sarcopenia was 40.9 % [95 % CI: 28.4 %-58.9 %]. The pooled mean difference for BMI between sarcopenic and non-sarcopenic patients was -2.62 (95 % CI: 3.22 to -2.01, p < 0.01).
Conclusion: This highlights that approximately 41 % of patients with CP have sarcopenia, and that this seems to be associated with a low BMI. Given the known adverse impact of sarcopenia on overall health, future studies should focus on standardizing sarcopenia screening, assessment and exploring its interplay with outcomes in CP patients.
期刊介绍：
Pancreatology is the official journal of the International Association of Pancreatology (IAP), the European Pancreatic Club (EPC) and several national societies and study groups around the world. Dedicated to the understanding and treatment of exocrine as well as endocrine pancreatic disease, this multidisciplinary periodical publishes original basic, translational and clinical pancreatic research from a range of fields including gastroenterology, oncology, surgery, pharmacology, cellular and molecular biology as well as endocrinology, immunology and epidemiology. Readers can expect to gain new insights into pancreatic physiology and into the pathogenesis, diagnosis, therapeutic approaches and prognosis of pancreatic diseases. The journal features original articles, case reports, consensus guidelines and topical, cutting edge reviews, thus representing a source of valuable, novel information for clinical and basic researchers alike.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
